Resolute Bio

About Resolute Bio

The startup develops peptide therapeutics that enhance immune function and reduce inflammation in severe central nervous diseases by enabling non-covalent attachment of proteins to red blood cells. This technology improves drug circulation and minimizes immunogenicity, thereby optimizing the efficacy of peptide and protein-based treatments.

The startup develops peptide therapeutics that enhance immune function and reduce inflammation in severe central nervous diseases by enabling non-covalent attachment of proteins to red blood cells. This technology improves drug circulation and minimizes immunogenicity, thereby optimizing the efficacy of peptide and protein-based treatments.

What does Resolute Bio do?

The startup develops peptide therapeutics that enhance immune function and reduce inflammation in severe central nervous diseases by enabling non-covalent attachment of proteins to red blood cells. This technology improves drug circulation and minimizes immunogenicity, thereby optimizing the efficacy of peptide and protein-based treatments.

Where is Resolute Bio located?

Resolute Bio is based in Beverly, United States.

How much funding has Resolute Bio raised?

Resolute Bio has raised $7.0M.

Location
Beverly, United States
Funding
$7.0M
Employees
5 employees

Resolute Bio

9
Relative Traction Score based on online presence metrics compared to companies in the same age group.

Executive Summary

The startup develops peptide therapeutics that enhance immune function and reduce inflammation in severe central nervous diseases by enabling non-covalent attachment of proteins to red blood cells. This technology improves drug circulation and minimizes immunogenicity, thereby optimizing the efficacy of peptide and protein-based treatments.

resolutebio.com200+
Beverly, United States

Funding

No specific funding rounds found.

Total Funding

$7.0M

Team (5+)

No team information available.

Company Description

The startup develops peptide therapeutics that enhance immune function and reduce inflammation in severe central nervous diseases by enabling non-covalent attachment of proteins to red blood cells. This technology improves drug circulation and minimizes immunogenicity, thereby optimizing the efficacy of peptide and protein-based treatments.

Sources:

This profile is AI-generated from web data and may contain inaccuracies. Want to correct or remove an entry? Owners can claim edits via their company email domain, and signed-in users can submit sourced suggestions.